Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

Saved in:

Bibliographic Details
Main Authors:	Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, Paola Facheris, Chiara Perugini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Journal of Dermatological Treatment
Online Access:	https://www.tandfonline.com/doi/10.1080/09546634.2024.2375102
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024-12-01)

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study
by: Tiago Torres, et al.
Published: (2025-06-01)

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
by: Nina Magnolo, et al.
Published: (2024-12-01)

Experience of using the drug upadacitinib in a child with severe atopic dermatitis
by: G. D. Alemanova, et al.
Published: (2025-06-01)

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience
by: Gioele Ghezzi, et al.
Published: (2024-11-01)

Dupilumab in children and adolescents with atopic dermatitis, a 52-week real-life experience: first report in Colombia
by: Daniela Meléndrez Vásquez, et al.
Published: (2024-10-01)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
by: Twan Sia, BA, et al.
Published: (2025-05-01)

Upadacitinib Monotherapy in Vitiligo Associated with Atopic Dermatitis: Killing Two Birds with One Stone
by: Lina Maria Magnanimi, et al.
Published: (2025-02-01)

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals
by: Giovanni Paolino, et al.
Published: (2024-12-01)

Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies
by: Claudia Paganini, et al.
Published: (2025-03-01)

A Case of Upadacitinib-Associated Ileus Secondary to Psoriasis Induced by Treatment of Atopic Dermatitis with Dupilumab
by: Liu X, et al.
Published: (2024-12-01)

Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry
by: Barbara Kind, et al.
Published: (2025-05-01)

Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report
by: Mario Valenti, et al.
Published: (2024-12-01)

Efficacy of upadacitinib in the management of atopic dermatitis, Crohn’s disease, and hidradenitis suppurativa: one treatment, multiple indications
by: Roberto Bueno-Filho, et al.
Published: (2025-08-01)

Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry
by: Florence Vroman, et al.
Published: (2025-12-01)

Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report
by: Katrina D Cirone, et al.
Published: (2025-02-01)

Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2025-04-01)

Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report
by: Zhaoyang Wang, et al.
Published: (2025-12-01)

Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients
by: Yu L, et al.
Published: (2025-03-01)

A case of psoriasis and atopic dermatitis-like rash induced by interleukin-17 and interleukin-23 inhibitors successfully controlled with upadacitinib
by: Toshiki Okazaki, MD, et al.
Published: (2025-09-01)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
by: Teppei Hagino, et al.
Published: (2024-12-01)

Mid-term Safety and Efficacy of Upadacitinib in Adolescents With Moderate-to-severe Atopic Dermatitis: A Real-life 34-Patient Multicenter Trial
by: F.J. Melgosa-Ramos, et al.
Published: (2025-04-01)

Atopic dermatitis
by: Stuart Carr, et al.
Published: (2024-12-01)

Atopic Dermatitis
by: D. Engler, et al.
Published: (2018-11-01)

ATOPIC DERMATITIS
by: L.S. Namazova, et al.
Published: (2006-02-01)

Efficacy and safety of upadacitinib through 140 weeks in Chinese adult and adolescent patients with moderate-to-severe atopic dermatitis: Post hoc analysis of the phase 3 Measure Up 1 and AD Up clinical trials
by: Li Zhang, et al.
Published: (2025-07-01)

Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
by: Francisco Javier Melgosa Ramos, et al.
Published: (2025-08-01)

Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study
by: Stephan Weidinger, et al.
Published: (2025-03-01)

Unmet needs in atopic dermatitis management: an expert consensus
by: Annalisa Patrizi, et al.
Published: (2022-07-01)

Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us?
by: Edoardo Mortato, et al.
Published: (2025-12-01)

Atopic dermatitis - the review
by: Joanna Wrona, et al.
Published: (2025-01-01)

Profile of Transepidermal Water Loss in Non-Atopic Dermatitis and Atopic Dermatitis in Indonesian Adults
by: Damayanti, et al.
Published: (2025-03-01)

GROSS PROFITABILITY AND 52-WEEK HIGH PRICE
by: Nesrin Özkan
Published: (2021-07-01)

Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel
by: Alessandra Narcisi, et al.
Published: (2025-03-01)

Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)
by: Jonathan I. Silverberg, et al.
Published: (2025-07-01)

Access to Emollients in Atopic Dermatitis
by: Stephanie‐Lynn Ryan, et al.
Published: (2025-06-01)

The diagnosis and management of atopic dermatitis
by: H.F. Jordaan, et al.
Published: (2009-10-01)

Childhood Atopic Dermatitis in Taiwan
by: I-Jen Wang, et al.
Published: (2016-04-01)

Update Management of Atopic Dermatitis
by: Indri Widya Sari, et al.
Published: (2024-11-01)